Masimo Corporation
NASDAQ:MASIMedical - Devices
+$0.00 today
- Market cap
- $9.42B
- Beta
- 1.10
- P/E (TTM)
- 123.1
- EPS (TTM)
- $1.46
Volume 0.00M
Average 1.08M
MASI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Masimo CorporationNASDAQ: MASI
EBITDA · Q1 FY2026 · quarter ended Apr 2026
EBITDA dips below year-ago levels
Q1 FY2026 EBITDA of $85.5M fell 0.3% year over year, behind the +414.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.
Context
- EBITDA amounted to 22.6% of revenue in FY2025, up 15.0 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 2 analysts of $224.8M (-34.8%) for the fiscal year ending Jan 2027, a slowdown from the +317.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- $85.5M-10.1% QoQ
- Last fiscal yearJan 2026
- $344.6M+317.1% YoY
- LTMApr 2026
- $344.5M+414.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.3% | -23.6% | -23.2 pp |
| 1 year | +317.1% | -34.8% | -351.9 pp |
| 3-year CAGR | -1.0% | -8.9% | -7.9 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 344.6M USD
- Year-over-year change
- +317.1%
- 4-year CAGR
- +2.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-03 | 344.6M | +317.1% |
| FY2024 | 2024-12-28 | (158.7M) | -167.0% |
| FY2023 | 2023-12-31 | 236.7M | -33.4% |
| FY2022 | 2022-12-31 | 355.2M | +14.5% |
| FY2021 | 2021-12-31 | 310.3M | — |
EBITDA vs competitors
How MASI compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +414.9% is the highest of 11, against a peer median of -13.6%.
- EBITDA amounts to 22.1% of revenue for MASI, versus a peer median of 19.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.05B USD | +8.7% | +1.0% | 7.7% | |
| LTM Jun 2026 | $822.22M USD | +1.7% | +10.9% | 20.9% | |
| LTM Jun 2026 | $750M USD | -27.5% | — | 6.5% | |
| LTM Jun 2026 | $514.7M USD | -22.7% | — | 19.9% | |
| LTM Apr 2026 | $344.5M USD | +414.9% | -1.0% | 22.1% | |
| LTM Sep 2026 | $333M USD | -78.1% | -10.2% | 0.8% | |
| LTM Jun 2026 | €296.36M EUR | -4.5% | +4.4% | 24.3% | |
| LTM Jun 2026 | $174.78M USD | +55.7% | -13.0% | 22.3% | |
| LTM Jun 2026 | $125.3M USD | -91.1% | -55.0% | 1.9% | |
| LTM Sep 2026 | -$173.24M USD | -2.5% | — | 61.7% | |
| FY2025 | -€300.7M EUR | -84.8% | — | — | |
| Peer median (excluding MASI) | — | -13.6% | -4.6% | 19.9% | |
Competitors are the stored peer set for MASI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.24B | 2.04B | 2.05B | 2.09B | 1.53B |
| Cost of Revenue | 430.8M | 977M | 1.04B | 1.09B | 581.7M |
| Gross Profit | 808.4M | 1.06B | 1B | 1B | 945.2M |
| Gross Margin | 65.2% | 52.0% | 49.0% | 48.0% | 61.9% |
| Research & Development | 137.2M | 191.4M | 175.2M | 222.8M | 126.4M |
| Selling, General & Admin | 395.4M | 657.4M | 664M | 743.8M | 506M |
| Operating Expenses | 532.6M | 848.8M | 867M | 1.27B | 632.4M |
| Depreciation & Amortization | 35.6M | 136.1M | 98.3M | 103M | 38.8M |
| EBITDA | 310.3M | 355.2M | 236.7M | (158.7M) | 344.6M |
| EBITDA Margin | 25.0% | 17.4% | 11.6% | -7.6% | 22.6% |
| Operating Income | 275.8M | 210M | 136.5M | (266.7M) | 312.8M |
| Operating Margin | 22.3% | 10.3% | 6.7% | -12.7% | 20.5% |
| Interest Income | 900K | 1.8M | 3M | 4.8M | 3.4M |
| Interest Expense | 300K | 25.7M | 50.3M | 43.6M | 33.2M |
| Other Income / Expenses | (1.4M) | (16.6M) | (48.4M) | (38.6M) | (40.2M) |
| Income Before Tax | 274.4M | 193.4M | 88.1M | (305.3M) | 272.6M |
| Pre-Tax Margin | 22.1% | 9.5% | 4.3% | -14.6% | 17.9% |
| Income Tax Expense | 44.8M | 49.9M | 6.6M | (400K) | 64.9M |
| Net Income | 229.6M | 143.5M | 81.5M | (304.9M) | (151.5M) |
| Net Margin | 18.5% | 7.0% | 4.0% | -14.6% | -9.9% |
| EPS (Basic) | 4.16 | 2.68 | 1.54 | (5.72) | (2.83) |
| EPS (Diluted) | 3.98 | 2.60 | 1.51 | (5.72) | (2.80) |
| Weighted Avg Shares | 55.17M | 53.6M | 52.8M | 53.3M | 53.6M |
| Weighted Avg Shares (Diluted) | 57.68M | 55.2M | 54.1M | 53.3M | 54.2M |
Masimo Corporation
NASDAQ:MASI
Intrinsic Alpha fair value
Locked
Current Price
$179.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.